50,223 Shares in Novo Nordisk A/S $NVO Acquired by Havemeyer Place LP

Havemeyer Place LP purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 50,223 shares of the company’s stock, valued at approximately $2,555,000.

Other institutional investors have also made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $25,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $28,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.9%

NVO opened at $42.93 on Friday. The stock has a market capitalization of $191.66 billion, a PE ratio of 10.08, a P/E/G ratio of 3.83 and a beta of 0.78. The firm’s fifty day moving average price is $41.62 and its 200 day moving average price is $46.18. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion during the quarter. As a group, research analysts expect that Novo Nordisk A/S will post 3.46 EPS for the current fiscal year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: TD Cowen raised its 2030 GLP-1 sales forecast to $150 billion and expects Novo Nordisk to remain one of the two dominant leaders alongside Eli Lilly, implying continued long-term demand for obesity and diabetes therapies. GLP-1 Sales Forecast Jumps To $150 Billion By 2030
• Positive Sentiment: Novo Nordisk is expanding internationally as only 1%–2% of global patients currently use obesity drugs, suggesting a large untapped market if pricing and access improve over time. Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
• Positive Sentiment: Novo Nordisk announced a clinical supply agreement with Veru for a Phase 2b obesity trial testing Wegovy in combination with enobosarm, giving the company another potential path to extend its obesity franchise. Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial
• Neutral Sentiment: Investor attention is elevated ahead of Novo Nordisk’s ADA conference data releases and June 7 R&D event, which could create volatility depending on pipeline updates and clinical readouts. Novo Nordisk gains as investors position for ADA data and June 7 R&D event
• Neutral Sentiment: Novo Nordisk is also getting broad market attention as a “trending stock,” but that reflects heightened investor interest rather than a clearly stock-moving fundamental update. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research report on Tuesday, March 3rd. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Wall Street Zen raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research report on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.